We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

189 hedge funds and large institutions have $1.04B invested in ARS Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

23% more capital invested

Capital invested by funds: $840M → $1.04B (+$196M)

13% more call options, than puts

Call options by funds: $4.56M | Put options by funds: $4.04M

5.38% more ownership

Funds ownership: 84.63% → 90.01% (+5.4%)

9% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 34

5% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 55

1% more funds holding

Funds holding: 188 → 189 (+1)

Holders
189
Holders Change
+1
Holders Change %
+0.53%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
37
Increased
58
Reduced
55
Closed
34
Calls
$4.56M
Puts
$4.04M
Net Calls
+$519K
Net Calls Change
-$5.5M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$30.8M
2
TCM
Tyro Capital Management
Florida
+$19.4M
3
RCMNY
Rubric Capital Management (New York)
New York
+$16.5M
4
UBS Group
UBS Group
Switzerland
+$15.1M
5
Fidelity International
Fidelity International
Bermuda
+$7.88M

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$25.1M
2
MB
MPM BioImpact
Massachusetts
-$13.1M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$10.4M
4
EP
Eversept Partners
New York
-$7.05M
5
KPF
K2 Principal Fund
Ontario, Canada
-$5.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
GFM
151
GF Fund Management
China
$22.6K -$1.79K -184 -9%
Rockefeller Capital Management
152
Rockefeller Capital Management
New York
$22.1K +$8.69K +894 +89%
AB
153
Amalgamated Bank
New York
$22K +$1.66K +171 +10%
US Bancorp
154
US Bancorp
Minnesota
$17.2K -$973 -100 -6%
CAL
155
Capital Analysts LLC
Pennsylvania
$15K – – –
FFA
156
Farther Finance Advisors
California
$13.3K -$3.9K -401 -26%
TRCT
157
Tower Research Capital (TRC)
New York
$12.2K -$62.3K -6,404 -86%
HWA
158
Heritage Wealth Advisors
Virginia
$11.7K – – –
EB
159
Eastern Bank
Massachusetts
$8.74K +$7.29K +750 New
SS
160
SBI Securities
Japan
$8.73K +$496 +51 +7%
AF
161
Allworth Financial
California
$8.66K -$515 -53 -7%
GSWM
162
Golden State Wealth Management
California
$5.64K – – –
AW
163
Avion Wealth
Texas
$5K – – –
SCM
164
Sterling Capital Management
North Carolina
$4.68K +$2.52K +259 +181%
BLC
165
Brown, Lisle/Cummings
Rhode Island
$4.66K – – –
SWM
166
Spire Wealth Management
Virginia
$4.66K – – –
AAP
167
Arax Advisory Partners
Colorado
$4.3K +$2.34K +241 +188%
HHCP
168
Hilton Head Capital Partners
South Carolina
$4.25K +$3.55K +365 New
QCG
169
Quadrant Capital Group
Ohio
$4.04K – – –
Daiwa Securities Group
170
Daiwa Securities Group
Japan
$4K – – –
Optiver Holding
171
Optiver Holding
Netherlands
$3.03K -$934 -96 -27%
Bessemer Group
172
Bessemer Group
New Jersey
$3K – – –
QL
173
Quarry LP
New York
$2.91K +$2.43K +250 New
Comerica Bank
174
Comerica Bank
Texas
$2.53K +$963 +99 +84%
KFI
175
Key Financial Inc
Pennsylvania
$2.33K +$1.95K +200 New
5 6
7
8 9

SPRY Hedge Fund Activity: Q4 2025 in Review

189 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q4 2025, worth a combined $1.04B — up 23% from $840M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new SPRY positions and 34 closed out — a net gain of 3 holders — while 58 added to existing stakes and 55 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $30.8M. The largest seller was AllianceBernstein, cutting an estimated $25.1M.

  • 189 institutional investors held ARS Pharmaceuticals (SPRY) as of Q4 2025, up from 188 in Q3 2025.
  • Funds reported $1.04B of ARS Pharmaceuticals stock for Q4 2025, up 23% quarter-over-quarter.
  • 37 funds opened new ARS Pharmaceuticals positions in Q4 2025 and 34 closed out, a net change of +3 holders.
  • The largest ARS Pharmaceuticals buyer in Q4 2025 was Millennium Management, an estimated $30.8M added.
  • The largest ARS Pharmaceuticals seller in Q4 2025 was AllianceBernstein, an estimated $25.1M sold.

Based on aggregated 13F filings for Q4 2025.